2026-09-20T05:00:53Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1570992024-10-03T03:34:25Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Goentzel, Jarrod
Wertheimer, Sarah R.
Massachusetts Institute of Technology. Institute for Data, Systems, and Society
2024-10-02T17:30:26Z
2024-10-02T17:30:26Z
2024-09
2024-09-16T19:32:19.477Z
https://hdl.handle.net/1721.1/157099
Choosing at how many and which treatment centers to offer a gene therapy to patients is
a crucial decision which impacts how far the treatment has to be transported and how far
patients have to travel to receive treatment. Many gene therapies are for patients with severe diseases that make it difficult to travel. On the other hand, cold chain requirements
make shorter transportation preferable for gene therapies, and few centers have prior experience handling them. Using multi-criteria optimization modeling paired with local input,
this thesis explores different approaches to the gene therapy treatment center location selection decision and how these approaches would affect patients’ geographic accessibility to
treatment.
We focus on Brazil and a specific gene therapy product as our case study. We interview
local pharmaceutical company employees to understand the stakeholders involved in this
decision and the approaches being considered. We model how these approaches would affect patients’ geographic accessibility to treatment and discuss potential modifications to
our model. Finally, by means of an interactive workshop, we explore the decision-making
discussion between stakeholders in choosing which approach to follow.
We find that the approaches under consideration result in a wide range of geographic accessibility for patients. Early stage decisions have impacts across stages, and even therapies,
due to a reluctance to select new locations. Patients in the northwest of Brazil would need
stakeholders to consider candidate locations beyond government reference centers or those
with gene therapy experience, in order to have a treatment center nearby. Regarding facilitation, we find that quick, low-stakes modeling and joint discussion could allow stakeholders
to consider approaches they might not otherwise consider.
S.M.
Massachusetts Institute of Technology
Attribution 4.0 International (CC BY 4.0)
Copyright retained by author(s)
https://creativecommons.org/licenses/by/4.0/
Looking at the Map, Together: Modeling Treatment Center Location Selection and its Effects on Access to Gene Therapy in Brazil
Thesis
application/pdf
Master
Master of Science in Technology and Policy
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="76dafab7-7886-4464-af74-28dfedf50319">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Title>Looking at the Map, Together: Modeling Treatment Center Location Selection and its Effects on Access to Gene Therapy in Brazil</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2024-09</PublicationDate>
<Authors>
<Author>
<DisplayName>Wertheimer, Sarah R.</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>https://creativecommons.org/licenses/by/4.0/</License>
<Abstract>Choosing at how many and which treatment centers to offer a gene therapy to patients is
a crucial decision which impacts how far the treatment has to be transported and how far
patients have to travel to receive treatment. Many gene therapies are for patients with severe diseases that make it difficult to travel. On the other hand, cold chain requirements
make shorter transportation preferable for gene therapies, and few centers have prior experience handling them. Using multi-criteria optimization modeling paired with local input,
this thesis explores different approaches to the gene therapy treatment center location selection decision and how these approaches would affect patients’ geographic accessibility to
treatment.
We focus on Brazil and a specific gene therapy product as our case study. We interview
local pharmaceutical company employees to understand the stakeholders involved in this
decision and the approaches being considered. We model how these approaches would affect patients’ geographic accessibility to treatment and discuss potential modifications to
our model. Finally, by means of an interactive workshop, we explore the decision-making
discussion between stakeholders in choosing which approach to follow.
We find that the approaches under consideration result in a wide range of geographic accessibility for patients. Early stage decisions have impacts across stages, and even therapies,
due to a reluctance to select new locations. Patients in the northwest of Brazil would need
stakeholders to consider candidate locations beyond government reference centers or those
with gene therapy experience, in order to have a treatment center nearby. Regarding facilitation, we find that quick, low-stakes modeling and joint discussion could allow stakeholders
to consider approaches they might not otherwise consider.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>